

DMD #86330

Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody

Jean-Philippe Émond, Adrien Labriet, Sylvie Desjardins, Michèle Rouleau, Lyne Villeneuve, H el ene Hovington, Herv e Brisson, Louis Lacombe, David Simonyan, Patrick Caron, Martine P erigny, Bernard T etu, John K. Fallon, Kathrin Klein, Philip C. Smith, Ulrich M. Zanger, Chantal Guillemette[†] and Eric L evesque[†]

Centre Hospitalier Universitaire (CHU) de Qu ebec Research Centre and Faculty of Medicine, Laval University, Qu ebec, Canada (JPE, SD, HH, HB, LL, MP, BT, EL)

CHU de Qu ebec Research Centre and Faculty of Pharmacy, Laval University, Qu ebec, Canada (AL, MR, LV, PC, CG)

Statistical and Clinical Research Platform, CHU de Qu ebec Research Centre, Qu ebec, Canada (DS)

Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (JKF, PSC)

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of T ubingen, T ubingen, Germany (KK, UMZ)

DMD #86330

Running head: Specific Quantification of UGT2B17

†Corresponding authors:

Eric Lévesque, M.D., Ph.D., FRCPC, Hematologist-Oncologist, CIHR clinician-scientist

Chantal Guillemette., Ph.D., Canada Research Chair in Pharmacogenomics

CHU de Québec Research Centre, R4720, 2705 Blvd. Laurier

Québec, QC, Canada, G1V 4G2

Tel. (418) 654-2296; Fax (418) 654-2761

eric.levesque@crchudequebec.ulaval.ca

chantal.guillemette@crchudequebec.ulaval.ca

NUMBER OF:

Table: 1

Figures: 6

Supplemental Tables: 2

Supplemental Figures: 7

References: 55

NUMBER OF WORDS:

Abstract: 251

Introduction: 588

Materials and Methods: 1 073

Results: 883

Discussion: 1 426

Total words count: 3970

DMD #86330

Abbreviations

WB: Western blot

CNV: Copy number variation

DHT: Dihydrotestosterone

FOXA1: Forkhead box protein A1

LAPC4: Prostate cancer xenograft cells

LD: Linkage disequilibrium

LLOQ: Lower limit of quantification

LNCaP: Lymph node carcinoma of the prostate

MS: Mass spectrometry

PCa: Prostate cancer

PCR: Polymerase chain reaction

qPCR: Quantitative real-time polymerase chain reaction

SNP: Single-nucleotide polymorphism

UGT: Uridine diphospho-glucuronosyltransferase

DMD #86330

Abstract

The accurate quantification of the metabolic enzyme UGT2B17 has been hampered by the high sequence identity with other UGT2B enzymes (as high as 94%) and by the lack of a specific antibody. Knowing the significance of the UGT2B17 pathway in drug and hormone metabolism and cancer, we developed a specific monoclonal antibody (EL-2B17mAb), initially validated by the lack of detection in liver microsomes of an individual carrying no *UGT2B17* gene copy and in supersomes expressing UGT2B enzymes. Immunohistochemical detection in livers reveals a strong labeling of bile ducts and variable labeling of hepatocytes. Expression levels assessed by immunoblotting were highly correlated to mass spectrometry-based quantification ($r = 0.93$) and three major expression patterns (absent, low or high) were evidenced. Livers with very low expression were carriers of the functional rs59678213 G variant, which is located in the binding site for the transcription factor Forkhead Box A1 (FOXA1) of the *UGT2B17* promoter. The highest expression was observed for individuals carrying at least one rs59678213 A allele. A multiple regression analysis indicated that the number of gene copies explained only 8% of UGT2B17 protein expression, 49% when adding rs59678213 and reached 54% when including sex. The novel EL-2B17mAb antibody allowed specific UGT2B17 quantification and exposed different patterns of hepatic expression. It further suggests that FOXA1 is a key driver of UGT2B17 expression in the liver. The availability of this molecular tool will help characterize UGT2B17 level in various disease states and establish more precisely the UGT2B17 enzyme contribution to drug and hormone metabolism.

DMD #86330

Introduction

Uridine diphospho-glucuronosyltransferases (UGTs) are key enzymes that act at multiple levels in the human body, including in the liver, kidneys, intestines, prostate and multiple other tissues (Beaulieu et al., 1996; Turgeon et al., 2001; Guillemette et al., 2014; Stingl et al., 2014; Margaillan et al., 2015a). This metabolic pathway inactivates many commonly used drugs such as statins, antidepressants and antineoplastic agents (Balliet et al., 2009; Kang et al., 2010; Guillemette et al., 2014; Stingl et al., 2014). Of the 19 human UGT enzymes, UGT2B17 has been found to specifically metabolize and inactivate sex-steroid hormones such as testosterone and dihydrotestosterone in the prostate (Beaulieu et al., 1996). UGT2B17 activity is highly variable in tissues such as the liver (Lazarus et al., 2005; McCarroll et al., 2006; Liu et al., 2014; Margaillan et al., 2015b; Bhatt et al., 2018), and therefore a better understanding of determinants of UGT2B17 protein expression could help to predict its influence on xenobiotics and endobiotics under normal conditions and disease states. Until now, the quantification of UGT2B17 has been hampered by the high sequence identity with other UGT2B subfamily members. For instance, UGT2B15 shares more than 94% of its amino acid sequence with UGT2B17 (Beaulieu et al., 1996). This explains, at least in part, the current lack of a specific antibody, which does not cross-react with any of the other UGT2B members, namely UGT2B4, 2B7, 2B10, 2B11, 2B15 and 2B28 (Guillemette et al., 2010; Guillemette et al., 2014). Thus, the quantification of UGT2B17 has been mostly extrapolated from correlative studies of RNA expression and enzymatic activities (Lazarus et al., 2005; Izukawa et al., 2009; Chen et al., 2010; Jones and Lazarus, 2014; Liu et al., 2014). These approaches have limitations, especially in the context of splicing mechanisms and overlapping substrate specificities (Hum et al., 1999; Guillemette et al., 2014; Tourancheau et al., 2016; Tourancheau et al., 2018).

DMD #86330

More recently, mass spectrometry (MS)-based quantification of UGT2B17 was developed using signature peptides (Fallon et al., 2013; Margaillan et al., 2015b; Bhatt et al., 2018). A recent study based on MS quantification showed that 26% of the variability of hepatic UGT2B17 protein expression could be explained with a model considering age, sex, and five genetic variations (rs7436962, rs9996186, rs28374727, rs4860305 and gene copy number (CNV)) (Bhatt et al., 2018). It is thus likely that additional molecular determinants exist, as the majority of this variability remains unexplained. One single nucleotide variation (SNP) in the *UGT2B17* gene rs59678213, located in a Forkhead Box Protein A1 (FOXA1) binding site in the promoter region, influenced *UGT2B17* gene expression in prostate cancer cells (Hu et al., 2010), but its impact on expression in human tissues remains to be elucidated. Another study suggested that rs6817882, also located in the *UGT2B17* promoter region, could be of interest (Liu et al., 2014). This marker is in strong linkage disequilibrium (LD) with rs59678213 and was correlated with RNA levels in the liver (Liu et al., 2014). However, the impact of these SNPs on UGT2B17 protein expression was not quantified in these two studies (Hu et al., 2010; Liu et al., 2014).

The first objective of this study was to develop a specific monoclonal antibody for a more accurate quantification of the UGT2B17 enzyme in human tissues. The second objective was to evaluate the heterogeneity in UGT2B17 protein expression observed in the human liver and gain further insights into molecular determinants of its expression. A specific antibody would be an additional tool for the scientific community to quantify the UGT2B17 enzyme and expedite the study of this important pathway involved in major metabolic functions.

DMD #86330

Materials and Methods

Human tissue specimens

Supersomes overexpressing human UGT2B enzymes were purchased from Corning Life Sciences (Woburn, MA). Microsomes from pooled human livers (HLM), intestine (HIM) and kidney (HKM) were purchased from Xenotech (Lexena, KS). Forty-eight human liver specimens from Caucasian healthy donors, from an equal number of males and females, were available for this study. The characteristics of the donors were described previously (Sumida et al., 1999; Gomes et al., 2009). Paraffin-embedded normal liver samples were available from four additional individuals. Written consent was obtained from donors and the study was approved by the ethics committee of the CHU de Québec, Laval University (#2012-245; 5.7.02.05 (34.05.08)).

Production of the UGT2B17 Protein Monoclonal Antibody

The monoclonal antibody directed against the UGT2B17 protein was produced using the custom monoclonal service at GenScript (Piscataway, NJ) according to their proprietary approach. An immunogenic peptide 83-KNDLEDFFMKMFDRWTY-99 (**Supplemental Fig.1**) was selected based on immunogenicity and specificity relative to the sequence of other human proteins, including the six other UGT2Bs. The clone #8B7E3-1 was used to produce the final antibody named EL-2B17mAb. Hybridoma cells were grown in low IgG bovine serum and the monoclonal antibody was purified from the culture medium by protein A/G affinity chromatography.

UGT2B17 mRNA and protein expression

UGT2B17 mRNA expression levels were assessed in 11 livers for which mRNA was available, as previously described (Chouinard et al., 2006; Lepine et al., 2010) using *36B4* as an internal

DMD #86330

amplification standard. The location of the primers is displayed in **Supplemental Fig.1**. Quantification of hepatic UGT2B17 by targeted proteomics for 48 livers with the signature peptide shown in **Supplemental Fig.1** was previously reported (Margaillan et al., 2015b). The lower level of quantification (LLOQ) was set at 0.2 pmol/mg protein. Quantification of hepatic UGT2B17 by WB was performed for 32 individual liver samples using available microsomal proteins. Supersomes (0.5 μ g) and microsomes (2 or 10 μ g) were mixed with Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA), heated at 100°C for five minutes, separated on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The membranes were blocked with PBS containing 0.2% Igepal (Sigma Aldrich, St-Louis, MO) and 5% dry milk, and then probed with the EL-2B17mAb monoclonal antibody (1:2000) overnight using standard protocols. The pan-UGT2B EL-93 polyclonal antibody (1:2000) was also used as described in a previous study (Levesque et al., 1997).

Immunohistochemistry

Sections (5 μ m) of paraffin-embedded normal liver samples were deparaffinized, rehydrated, and processed using a PT Link system (Agilent Technologies, Mississauga, ON, Canada). Heat-induced epitope retrieval was achieved using the EnVision FLEX Target Retrieval Solution, Low pH (Agilent) and tissues were stained with EL-2B17mAb (1:1000) using the IDetect SuperStain HRP polymer kit (Empire Genomics, Buffalo, NY, USA) as per the manufacturer's instructions.

UGT2B17 genetic status

Genotypes were assessed for the 48 individuals using available material consisting of DNA isolated from human liver specimens. CNV of the *UGT2B17* gene was determined as described previously (McCarroll et al., 2006; Menard et al., 2009). For rs59678213, a PCR amplicon spanning the promoter region was sequenced to assess the genotype. The amplification was

DMD #86330

performed in 25 μ L reactions containing 50 ng genomic DNA, 0.2 mM each dNTP (deoxynucleotide Solution Mix of dATP, dCTP, dGTP and dTTP), 3 mM $MgCl_2$, 0.3 mM each of the two primers (F: 5'-CCTCTCACCTGCCACTGTTC-3' and R: 5'-CATCTGCCAGAAGGACATCAAATT-3') and 1.25 units AmpliTaq Gold 360 DNA Polymerase (Thermo Fisher Scientific, Waltham, MA). The reaction was incubated at 95°C for 10 minutes, followed by 35 cycles of 95°C for 30 seconds, 62°C for 40 seconds and 72°C for 30 seconds, with a final elongation step at 72°C for seven minutes. Sanger sequencing was done using an ABI 3700 automated sequencer (Applied Biosystems, Foster City, CA). Allele frequency of the rs59678213 and rs6817882 variants and calculation of their linkage disequilibrium among ethnic groups from the 1000 Genomes Project Phase 3 were obtained through the *Ensembl genome browser* release 94 – October 2018, assembly GRCh37.p13, accessed on November 26, 2018. CNV of the *UGT2B17* gene in the same ethnic groups were obtained from Xue et al. (Xue et al., 2008).

Reporter gene assays

The human *UGT2B17* DNA promoter construct (–2413 to +1) was isolated as described in a previous study (Beaulieu et al., 1997). Using this construct as the template, we generated a construct containing guanine at position –155 (corresponding to rs59678213) using Q5 Site-Directed Mutagenesis kit reagents (New England Biolabs, ON, Canada) and the primers 5'-GAGTAATTGTgAATATAAAAGAACACC-3' (forward) and 5'-TAGTCAAGCAATAATTTTTATGAC-3' (reverse). Mutagenesis of these constructs was performed to generate an adenine at position –2033 (corresponding to rs6817882) using the primers 5'-ATTTTATATTaTTTTATGCTCAGTACCTG-3' (forward) and 5'-AATCTGAGAGGGTCCTTC-3' (reverse). The prostate cancer LNCaP (lymph node carcinoma

DMD #86330

of the prostate) and the hepatocellular carcinoma HepG2 cell lines were purchased from the American Type Culture Collection (Manassas, VA). The HuH7 cell line was obtained from the Japanese Collection of Research Bioresources Cell Bank (Tokyo, Japan), whereas the PCa cell line LAPC4 (prostate cancer xenograft cells) was a kind gift from Dr. F. Pouliot (CHU de Québec Research Centre, Laval University, QC, Canada). Cells were maintained in RPMI-1640 medium (LNCaP) or DMEM (LAPC4, HepG2, HuH7) supplemented with 10% (v/v) FBS and antibiotics (100 IU/mL penicillin and 100 pg/mL streptomycin). RPMI-1640 for LNCaP culture was also supplemented with 2 mM glutamine. Culture medium components were all from Wisent Bioproducts (St-Bruno, QC, Canada). All transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and OptiMEM Reduced-Serum Medium (Life Technologies, Burlington, ON, Canada). Cells were plated into 24-well plates at a density of 1×10^5 (HepG2 and HuH7), 8.0×10^4 (LNCaP), or 2×10^5 (LAPC4) cells/well. For the luciferase assays, cells were transfected 24 hours after plating with 200 ng (HepG2 and HuH7) or 500 ng (LNCaP and LAPC4) of the appropriate constructs and 20 ng (HepG2 and HuH7) or 50 ng (LNCaP and LAPC4) of the Renilla luciferase construct (internal control). Cells were lysed 48 hours after transfection and assessed for luciferase activity using Dual-Luciferase Reporter Assay kit reagents (Promega, Madison, WI).

Statistical Analysis

Differences in UGT2B17 expression among genetic groups were confirmed using the Kruskal-Wallis test and Wilcoxon Mann Whitney test was used for sex. Correlation analysis was performed by the Spearman rank method. A multiple regression analysis was performed to evaluate the associations between UGT2B17 protein expression, sex and genotype. Differences between constructs in luciferase assays were tested using a two-tailed Student's t-test. A value of

DMD #86330

$P < 0.05$ was considered statistically significant. Analyses were corrected for the alpha error using the Bonferroni adjustment method. All statistical analyses were performed with the software SAS 9.4 by SAS Institute Inc. (Cary, NC).

DMD #86330

Results

EL-2B17mAb is a specific human UGT2B17 monoclonal antibody

The peptide sequence 83-KNDLEDFFMKMFDRWTY-99, unique to UGT2B17 among human UGT2B proteins (**Table 1; Supplemental Fig.1**) was chosen to produce the mouse monoclonal EL-2B17mAb antibody. The specificity of EL-2B17mAb was initially evaluated using supersomes overexpressing individual human UGT2B proteins. A protein band was detected only in the UGT2B17 supersomes at the expected molecular weight of 55 kDa (**Fig.1A**). The unique reactivity with the UGT2B17 protein was further confirmed with additional recombinant UGT2B enzymes, namely UGT2B11 and UGT2B28, not commercially available as supersomes (**Supplemental Fig.2**). The antibody was subsequently tested in major drug metabolizing tissues, displaying a strong signal in the liver and intestine and none in the kidney, consistent with the known tissue distribution of UGT2B17 (**Fig.1B**). Lastly, there was no signal in a UGT2B17-deficient HLM from an individual carrying no *UGT2B17* gene copy, proficient in the expression of other UGT2B enzymes (not shown), confirming the identity of the detected protein band as UGT2B17 and the specificity of the UGT2B17mAb (**Fig.1C**). Normal liver tissues from four individuals labeled with EL-2B17mAb by immunohistochemistry (IHC) revealed a strong labeling of bile duct epithelial cells (**Fig.2, Supplemental Fig.3**). By contrast, a widely variable labeling intensity was noted for hepatocytes among liver samples, and within each sample. Hepatocytes of the periportal zones were more intensely labeled and displayed a preferential nuclear labeling whereas hepatocytes in the centrilobular regions were weakly labeled. The intensity of cytoplasmic staining was variable, from strong to moderate in liver A, which displayed strongest overall labeling (**Fig.2**), to weak or undetected in the three other livers

DMD #86330

(**Supplemental Fig.3**). Initial experiments also suggest that the antibody does not impair UGT2B17 activity in microsomes (data not shown).

Gene deletion and the genetic variant rs59678213 largely contribute to the highly variable hepatic UGT2B17 expression.

The relative UGT2B17 protein expression levels assessed by WB in HLM samples was highly variable (CV = 118%) and correlated with the values obtained by quantitative MS for these same samples ($r = 0.93$; $P < 0.0001$) (**Fig.3**). A significant correlation with *UGT2B17* mRNA expression was also observed with protein abundance assessed by MS ($r = 0.70$, $P = 0.038$) and WB ($r = 0.75$, $P = 0.009$) for a subset of tested livers for which mRNA was available (not shown). According to *UGT2B17* CNV and based on quantification data, samples were categorized in three groups corresponding to no gene copy (n=9), one gene copy (n=21), and two gene copies (n=18) (**Fig.4**). As expected, the UGT2B17 protein was undetected by MS in the group with no gene copy (below LLOQ of 0.2 pmol/mg protein). The median protein abundance in carriers of one gene copy was very similar to the value observed for those carrying two gene copies (0.45 vs. 0.43; $P = 1.0$). A significant variability within groups was observed with 156% CV and 169% CV, in carriers of one and two gene copies, respectively. Based on this high variability, not explained by the number of *UGT2B17* gene copy, we next determined the association between UGT2B17 protein expression and the occurrence of a functional variation located in the FOXA1 binding sequence of the *UGT2B17* promoter, warranted by the frequent occurrence of this genetic variation, including in individuals of European descent (**Fig.5; Supplemental Table 1**). Irrespective of the *UGT2B17* gene copy number, livers carrying the rs59678213 A allele expressed high UGT2B17 levels, whereas all others comprised of only rs59678213G allele showed low expression. This was observed with quantification by both WB

DMD #86330

(**Fig.6A, Supplemental Fig.4, Supplemental Fig.5**) and MS (**Supplemental Table 2; Fig.6B-C**). In a further analysis taking sex into account, female carriers of the rs59678213G allele presented significantly lower UGT2B17 protein levels than male subjects (median levels of 0.27 versus 0.32 pmol/mg protein; $P = 0.026$) whereas there was no difference between sex for rs59678213A carriers displaying much higher expression (~40-fold). A multiple regression analysis indicated that at least one gene copy, rs59678213A and male sex are significantly associated with greater UGT2B17 expression. It further indicated that the number of gene copy explained only 8% of UGT2B17 protein expression, 49% when adding rs59678213 and reached 54% when including sex ($R^2 = 0.54$; multivariate linear regression). Since the UGT2B17 protein is considerably expressed in the prostate, we further tested the reactivity of EL-2B17mAb in prostate cancer cell lines. No expression of UGT2B17 was detected in LAPC4 cells by WB, consistent with the absence of the *UGT2B17* gene and very low expression in VCaP and 22rv1, homozygous for the rs59678213G allele. In contrast, high expression was observed in LNCaP cells homozygous for the rs59678213A allele (**Supplemental Fig.6**).

The genetic variant rs59678213 is a key driver of UGT2B17 expression *in vitro*.

The variants rs59678213 and rs6817882 significantly affecting *UGT2B17* mRNA expression were reported to be tightly linked (Hu et al., 2010; Liu et al., 2014). However, similar to the frequency of the *UGT2B17* gene deletion copy, we observed that their occurrence is highly variable between ethnic groups, ranging from 5 to 93% (**Fig.5**). Accordingly, we tested the functionality of these two markers using luciferase constructs engineered to reflect all combinations of alleles and tested them in cell models derived from the liver (HepG2 and HuH7) and prostate cancer cells carrying the *UGT2B17* gene (LNCaP and LAPC4) to identify the functional variant(s). Data supported the functional role of the rs59678213 variant as a major

DMD #86330

driver of UGT2B17 expression in LNCaP and LAPC4 prostate cancer cells as well as in hepatic HuH7 cells (**Supplemental Fig.7**). No difference in expression was observed in HepG2 cells in the presence of the rs59678213 variant (not shown).

DMD #86330

Discussion

Up to now, the accurate detection and quantification of human UGT2B17 proteins by WB analysis has been hampered by the lack of a highly specific monoclonal antibody. Indeed, the high sequence identity among UGT2B enzymes underlies the technical challenge of developing antibodies with no cross-reactivity with other subfamily members. Despite this very high sequence identity also observed in the UGT1A subfamily, specific monoclonal antibodies have been developed for UGT1A9 (Oda et al., 2012) and UGT1A10 (Oda et al., 2017), but are lacking for most UGT2B members. Several previous studies have used RNA expression and enzymatic kinetics as a surrogate to protein quantification (Lazarus et al., 2005; Izukawa et al., 2009; Chen et al., 2010; Jones and Lazarus, 2014; Liu et al., 2014). However, there are inherent limitations with these methods such as the presence of extensive alternative splicing events (Tourancheau et al., 2016; Tourancheau et al., 2018) and the intrinsic overlapping substrate specificities characterizing these enzymes (Belanger et al., 1998; Guillemette et al., 2010; Guillemette et al., 2014). More recently, to circumvent this technical issue related to the absence of highly specific UGT antibodies, MS-based methods were developed to accurately quantify UGT isoforms in human samples using small signature peptides (Sakamoto et al., 2011; Fallon et al., 2013; Sato et al., 2014; Margailan et al., 2015b; Bhatt et al., 2018).

The specificity of the EL-2B17mAb monoclonal antibody produced in this study is an important additional molecular tool capable of specifically detecting the UGT2B17 protein both in WB and IHC, and could expedite clinical advances on the significance of UGT2B17 in drug metabolism (Turgeon et al., 2003; Kang et al., 2010; Sun et al., 2010; Taghavi et al., 2017; Kahma et al., 2018) and cancer biology (Nadeau et al., 2011; Gruber et al., 2013; Bhoi et al., 2016; Li et al., 2016). It is the first antibody with a unique specificity for UGT2B17, without any cross-

DMD #86330

reactivity to any other human UGT2B enzymes, including the highly similar UGT2B15. The specificity of the antibody for the protein was conclusively demonstrated by the absence of protein detection in a UGT2B17-deficient liver, the latter expressing other UGT2B enzymes. Moreover, the fact that the correlation between immunoblotting and MS analyses reached 93% reinforces the notion that both methods are accurate to quantify UGT2B17. The lower degree of correlation between mRNA and protein quantification methods highlights the added value of the more precise assessment of UGT2B17 enzyme in the liver afforded by protein quantification. Quantification by immunoblotting with EL-2B17mAb may constitute a method of choice to assess the 55-kDa canonical UGT2B17 isoform.

Immunohistochemistry of four liver samples further revealed that UGT2B17 is expressed in the nucleus and cytoplasm of bile ducts and hepatocytes located in the periportal zone 1 region, in close contact with blood from the systemic and splanchnic circulations. Quantification of UGT2B17 by immunoblotting in multiple liver samples using EL-2B17mAb, strikingly revealed high UGT2B17 expression in nearly half of the specimens whereas it was undetected or barely detectable in the other half. It led us to evaluate whether the *UGT2B17* gene copy number was responsible for this *on* or *off* expression pattern. Amongst the livers tested, we found that 9 out of 48 samples had no copy of the gene, explaining the absence of expression in those samples. For all the other samples, the presence of one or two gene copies did not affect protein expression significantly, contrary to our expectation. Although the reasons for this are currently not understood, it should be noted that a recent analysis of *CYP2E1* copy number variation in liver and lymphocytes led to the conclusion that its expression is gene dosage-insensitive (Tremmel et al., 2016). In contrast, genotype of the rs59678213 variant located in the FOXA1 binding site of the promoter region of UGT2B17 (Hu et al., 2010) explained a much larger fraction of

DMD #86330

variability compared to copy number and the A allele was largely associated with the high UGT2B17 expression pattern. This common genetic variation, for which the genotype varies importantly across ethnic groups (**Fig.5; Supplemental Table 1**), was previously identified to affect FOXA1 binding to the *UGT2B17* promoter in prostate cancer cells by Hu and collaborators (Hu et al., 2010). Our functional analysis in liver and prostate cancer cells supported that this genetic variant significantly impacts *UGT2B17* expression. It is possible to infer that the rs59678213 explains a significant proportion of the enzyme hepatic expression since it is in strong linkage with rs6817882 in Caucasians, which was also found to be associated with a significant variation of UGT2B17 expression in the liver (Liu et al., 2014). Indeed, the high expression phenotype observed in WB was systematically associated with the presence of the rs59678213 A-variant. On the other hand, the absent or marginal expression phenotype was persistently associated with the rs59678213 G-variant or complete gene deletion. Overall, based on the protein expression data, the inclusion of the *UGT2B17* genetic status including the rs59678213 genetic variant and the CNV, along with sex, as previously reported from mRNA expression data (Gallagher et al., 2010), explains more than 50% of the variability of UGT2B17 protein expression in the liver. This knowledge represents an important finding since the current practice essentially considers the gene copy number to predict UGT2B17 expression levels (Gallagher et al., 2007; Wang et al., 2012; Kahma et al., 2018), here demonstrated to only partially reflect UGT2B17 expression. Based on the observed *UGT2B17* gene deletion frequency and the occurrence of the rs59678213 G genotype among ethnic groups, our results suggest a high expression of the UGT2B17 enzyme in the African population that displays a low deletion frequency and a prevalence of the rs59678213 A allele of 95%. By contrast, a high expression of UGT2B17 is expected in only ~15% of Asians (Chinese and Japanese) given the gene deletion

DMD #86330

frequency and the low prevalence of the rs59678213 A genotype, in only 18-23% of the Asian population.

Other known determinants of UGT2B17 protein expression were previously described such as age and additional germline single nucleotide variations (Liu et al., 2014; Bhatt et al., 2018), which were not tested herein due to the limited number of liver samples whereas rs59678213 and rs6817882 were not included in a previous study comprised of a much more significant number of liver samples (Bhatt et al., 2018). Based on our observations, it will be critical to test the variation rs59678213 in large cohorts to further our understanding of molecular determinants of UGT2B17 expression.

A major strength of this study is the development of the first monoclonal antibody with unique specificity for UGT2B17, and its validation by the analysis of a UGT2B17-negative liver and through correlation with proteomics quantification. It enables an accurate assessment of UGT2B17 by immunoblotting in human samples, accessible to most laboratories as well as by immunohistochemistry. To our knowledge, with the exception of the previously described specific polyclonal UGT2B28 antibody, also validated in UGT2B28-deficient samples (Belledant, 2016), it should be appreciated that the specificities of other antibodies directed against UGT2B members remain to be demonstrated and should be formally evaluated before conducting any translational studies in human samples. For instance, as highlighted in a recent study (Rouleau et al., 2016), a monoclonal anti-UGT2B10 showed significant reactivity for several UGT2B proteins, namely the UGT2B7 protein highly abundant in the liver. Limitations of the current study are related to the limited sample size and the absence of ethnic groups other than Caucasians. Correlation with the enzymatic activity of UGT2B17 was not performed here due to the overlapping substrate specificities of UGT2B enzymes and the lack of a known

DMD #86330

specific probe substrate for the enzyme since testosterone and etiocholanolone are conjugated by other UGTs (Green et al., 1994; Levesque et al., 1997). Based on our data, it will also be required to evaluate whether UGT2B17 expression is influenced by the rs59678213 variation in additional tissues, namely intestine and prostate. Future research should also be directed towards finding additional molecular determinants of UGT2B17 expression, which may well be tissue-specific. Besides additional genetic variants in the *UGT2B17* gene locus, those affecting expression of the FOXA1 transcription factor might also be of importance. This knowledge will help understand the biological impact of this enzyme in health and diseases, namely on the endocrine system (Juul et al., 2009; Mouritsen et al., 2018), osteoporosis (Yang et al., 2008), carcinogen exposure (Chen et al., 2010), head and neck cancer (Mafune et al., 2015), prostate cancer (Kpoghomou et al., 2013; Li et al., 2016), chronic lymphocytic leukemia (Gruber et al., 2013; Bhoi et al., 2016), pediatric cancer (Ishimaru et al., 2017) and on the inactivation of antineoplastic and other therapeutic agents (Kang et al., 2010; Sun et al., 2010; Wang et al., 2012).

Conclusion

We developed a monoclonal antibody that specifically recognizes UGT2B17 in the liver, with no cross-reactivity with other UGT2B enzymes, such as UGT2B7 and UGT2B15, which are both involved in steroids and drug glucuronidation. Detection of UGT2B17 by immunoblotting revealed a high degree of variations in the liver, displaying a remarkable *on* or *off* expression pattern and was also effective for IHC experiments with liver samples. Although our work exposes key determinants of UGT2B17 expression in the liver, other significant variations remain to be explained in future studies with larger cohorts, especially in the UGT2B17 rs59678213A high expressors subgroup. The availability of a specific monoclonal UGT2B17

DMD #86330

antibody will help speed up discoveries to clarify mechanisms of its regulation and variability in the liver and extrahepatic tissues to ultimately appraise its influence on human diseases and drug inactivation.

DMD #86330

Authorship Contribution:

Participated in study concept, design, and supervision: EL, CG

Statistical analysis: JPE, AL, DS

Conducted experiments: AL, SD, LV, HH, HB, PC, JKF, KK.

Contributed samples or analytic tools: MP, BT, LL, JKF, KK, PCS, UMZ.

Interpretation of data: all authors.

Drafting of the manuscript: JPE, MR, CG, EL.

Critical revision of the manuscript for important intellectual content: all authors.

Conflicts of interest

The authors have no conflict of interest to disclose

DMD #86330

References

- Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, and Lazarus P (2009) Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. *Cancer Res* **69**:2981-2989.
- Beaulieu M, Levesque E, Hum DW, and Belanger A (1996) Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. *J Biol Chem* **271**:22855-22862.
- Beaulieu M, Levesque E, Tchernof A, Beatty BG, Belanger A, and Hum DW (1997) Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. *DNA Cell Biol* **16**:1143-1154.
- Belanger A, Hum DW, Beaulieu M, Levesque E, Guillemette C, Tchernof A, Belanger G, Turgeon D, and Dubois S (1998) Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. *J Steroid Biochem Mol Biol* **65**:301-310.
- Belledant A, Hovington, H., Garcia, L., Caron, P., Brisson, H., Villeneuve, L., Simonyan, D., Têtu, B., Fradet, Y., Lacombe, L., Guillemette, C. and Lévesque E. (2016) The UGT2B28 Sex-Steroid Inactivation Pathway is a Regulator of Steroidogenesis and Modifies Risk of Prostate Cancer Progression. *Eur Urol* **69**:601-609.
- Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R, Broeckel U, Thornton TA, Nickerson DA, Schuetz EG, Amory JK, Leeder JS, and Prasad B (2018) Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex. *Drug Metab Dispos* **46**:888-896.

DMD #86330

- Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, Juliusson G, Sutton LA, and Mansouri L (2016) UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? *Haematologica* **101**:e63-65.
- Chen G, Giambrone NE, Jr., Dluzen DF, Muscat JE, Berg A, Gallagher CJ, and Lazarus P (2010) Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. *Cancer Res* **70**:7543-7552.
- Chouinard S, Pelletier G, Belanger A, and Barbier O (2006) Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. *Endocrinology* **147**:5431-5442.
- Fallon JK, Neubert H, Hyland R, Goosen TC, and Smith PC (2013) Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. *J Proteome Res* **12**:4402-4413.
- Gallagher CJ, Balliet RM, Sun D, Chen G, and Lazarus P (2010) Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. *Drug Metab Dispos* **38**:2204-2209.
- Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, and Lazarus P (2007) The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. *Cancer Detect Prev* **31**:310-315.
- Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, and Zanger UM (2009) Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. *Pharmacogenomics* **10**:579-599.

DMD #86330

- Green MD, Oturu EM, and Tephly TR (1994) Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. *Drug Metab Dispos* **22**:799-805.
- Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, Le T, Zehetmayer S, Mannhalter C, Gaiger A, Shehata M, Fleiss K, Skrabs C, Levesque E, Vanura K, Guillemette C, and Jaeger U (2013) Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. *Blood* **121**:1175-1183.
- Guillemette C, Levesque E, Harvey M, Bellemare J, and Menard V (2010) UGT genomic diversity: beyond gene duplication. *Drug Metab Rev* **42**:24-44.
- Guillemette C, Levesque E, and Rouleau M (2014) Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. *Clin Pharmacol Ther* **96**:324-339.
- Hu DG, Gardner-Stephen D, Severi G, Gregory PA, Treloar J, Giles GG, English DR, Hopper JL, Tilley WD, and Mackenzie PI (2010) A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3alpha,17beta-diol glucuronide. *Mol Pharmacol* **78**:714-722.
- Hum DW, Belanger A, Levesque E, Barbier O, Beaulieu M, Albert C, Vallee M, Guillemette C, Tchernof A, Turgeon D, and Dubois S (1999) Characterization of UDP-glucuronosyltransferases active on steroid hormones. *J Steroid Biochem Mol Biol* **69**:413-423.

DMD #86330

- Ishimaru S, Yuza Y, Kaneko T, and Urashima M (2017) Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer. *Pediatr Int* **59**:427-431.
- Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S, Sakaki T, and Yokoi T (2009) Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. *Drug Metab Dispos* **37**:1759-1768.
- Jones NR and Lazarus P (2014) UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues. *Drug Metab Dispos* **42**:529-536.
- Juul A, Sorensen K, Aksglaede L, Garn I, Rajpert-De Meyts E, Hullstein I, Hemmertsbach P, and Ottesen AM (2009) A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys. *J Clin Endocrinol Metab* **94**:1005-1011.
- Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, and Backman JT (2018) Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions(). *Drug Metab Dispos* **46**:141-150.
- Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, Haverfield E, and Ratain MJ (2010) A pharmacogenetic study of vorinostat glucuronidation. *Pharmacogenet Genomics* **20**:638-641.
- Kpoghomou MA, Soatiana JE, Kalembo FW, Bishwajit G, and Sheng W (2013) UGT2B17 Polymorphism and Risk of Prostate Cancer: A Meta-Analysis. *ISRN Oncol* **2013**:465916.

DMD #86330

- Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, and Wiener D (2005) Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. *Pharmacogenet Genomics* **15**:769-778.
- Lepine J, Audet-Walsh E, Gregoire J, Tetu B, Plante M, Menard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Belanger A, and Guillemette C (2010) Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. *J Clin Endocrinol Metab* **95**:2689-2698.
- Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, and Hum DW (1997) Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. *Pharmacogenetics* **7**:317-325.
- Li H, Xie N, Chen R, Verreault M, Fazli L, Gleave ME, Barbier O, and Dong X (2016) UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling. *Cancer Res* **76**:6701-6711.
- Liu W, Ramirez J, Gamazon ER, Mirkov S, Chen P, Wu K, Sun C, Cox NJ, Cook E, Jr., Das S, and Ratain MJ (2014) Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. *Hum Mol Genet* **23**:5558-5569.
- Mafune A, Hama T, Suda T, Suzuki Y, Ikegami M, Sakanashi C, Imai S, Nakashima A, Yokoo T, Wada K, Kojima H, and Urashima M (2015) Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma. *BMC Cancer* **15**:205.
- Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, and Guillemette C (2015a) Quantitative profiling of human renal UDP-

DMD #86330

glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. *Drug Metab Dispos* **43**:611-619.

Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, Smith PC, Zanger UM, and Guillemette C (2015b) Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential. *Drug Metab Dispos* **43**:1331-1335.

McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC, Dallaire S, Gabriel SB, Lee C, Daly MJ, and Altshuler DM (2006) Common deletion polymorphisms in the human genome. *Nat Genet* **38**:86-92.

Menard V, Eap O, Harvey M, Guillemette C, and Levesque E (2009) Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism. *Hum Mutat* **30**:1310-1319.

Mouritsen A, Busch AS, Aksglaede L, Rajpert-De Meyts E, and Juul A (2018) Deletion in the uridine diphosphate glucuronyltransferase 2B17 gene is associated with delayed pubarche in healthy boys. *Endocr Connect* **7**:460-465.

Nadeau G, Bellemare J, Audet-Walsh E, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L, Guillemette C, and Levesque E (2011) Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. *J Clin Endocrinol Metab* **96**:E1550-1557.

Oda S, Kato Y, Hatakeyama M, Iwamura A, Fukami T, Kume T, Yokoi T, and Nakajima M (2017) Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody. *Drug Metab Dispos* **45**:1027-1034.

DMD #86330

- Oda S, Nakajima M, Hatakeyama M, Fukami T, and Yokoi T (2012) Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues. *Drug Metab Dispos* **40**:1620-1627.
- Rouleau M, Tourancheau A, Girard-Bock C, Villeneuve L, Vaucher J, Duperre AM, Audet-Delage Y, Gilbert I, Popa I, Droit A, and Guillemette C (2016) Divergent Expression and Metabolic Functions of Human Glucuronosyltransferases through Alternative Splicing. *Cell Rep* **17**:114-124.
- Sakamoto A, Matsumaru T, Ishiguro N, Schaefer O, Ohtsuki S, Inoue T, Kawakami H, and Terasaki T (2011) Reliability and robustness of simultaneous absolute quantification of drug transporters, cytochrome P450 enzymes, and Udp-glucuronosyltransferases in human liver tissue by multiplexed MRM/selected reaction monitoring mode tandem mass spectrometry with nano-liquid chromatography. *J Pharm Sci* **100**:4037-4043.
- Sato Y, Nagata M, Tetsuka K, Tamura K, Miyashita A, Kawamura A, and Usui T (2014) Optimized methods for targeted peptide-based quantification of human uridine 5'-diphosphate-glucuronosyltransferases in biological specimens using liquid chromatography-tandem mass spectrometry. *Drug Metab Dispos* **42**:885-889.
- Stingl JC, Bartels H, Viviani R, Lehmann ML, and Brockmoller J (2014) Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. *Pharmacol Ther* **141**:92-116.
- Sumida A, Kinoshita K, Fukuda T, Matsuda H, Yamamoto I, Inaba T, and Azuma J (1999) Relationship between mRNA levels quantified by reverse transcription-competitive PCR

DMD #86330

- and metabolic activity of CYP3A4 and CYP2E1 in human liver. *Biochem Biophys Res Commun* **262**:499-503.
- Sun D, Chen G, Dellinger RW, Sharma AK, and Lazarus P (2010) Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. *Pharmacogenet Genomics* **20**:575-585.
- Taghavi T, St Helen G, Benowitz NL, and Tyndale RF (2017) Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. *Pharmacogenet Genomics* **27**:143-154.
- Tourancheau A, Margailan G, Rouleau M, Gilbert I, Villeneuve L, Levesque E, Droit A, and Guillemette C (2016) Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. *Pharmacogenomics J* **16**:60-70.
- Tourancheau A, Rouleau M, Guauque-Olarte S, Villeneuve L, Gilbert I, Droit A, and Guillemette C (2018) Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues. *Pharmacogenomics J* **18**:251-261.
- Tremmel R, Klein K, Winter S, Schaeffeler E, and Zanger UM (2016) Gene copy number variation analysis reveals dosage-insensitive expression of CYP2E1. *Pharmacogenomics J* **16**:551-558.
- Turgeon D, Carrier JS, Chouinard S, and Belanger A (2003) Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. *Drug Metab Dispos* **31**:670-676.
- Turgeon D, Carrier JS, Levesque E, Hum DW, and Belanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. *Endocrinology* **142**:778-787.

DMD #86330

Wang YH, Trucksis M, McElwee JJ, Wong PH, Maciolek C, Thompson CD, Prueksaritanont T, Garrett GC, Declercq R, Vets E, Willson KJ, Smith RC, Klappenbach JA, Opiteck GJ, Tsou JA, Gibson C, Laethem T, Panorchan P, Iwamoto M, Shaw PM, Wagner JA, and Harrelson JC (2012) UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. *Clin Pharmacol Ther* **92**:96-102.

Xue Y, Sun D, Daly A, Yang F, Zhou X, Zhao M, Huang N, Zerjal T, Lee C, Carter NP, Hurles ME, and Tyler-Smith C (2008) Adaptive evolution of UGT2B17 copy-number variation. *Am J Hum Genet* **83**:337-346.

Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, Zhou Q, Pan F, Chen Y, Zhang ZX, Dong SS, Xu XH, Yan H, Liu X, Qiu C, Zhu XZ, Chen T, Li M, Zhang H, Zhang L, Drees BM, Hamilton JJ, Papasian CJ, Recker RR, Song XP, Cheng J, and Deng HW (2008) Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. *Am J Hum Genet* **83**:663-674.

DMD #86330

Footnotes

Funding

This research was funded by the CHU de Québec (to EL), by the Canadian Institutes of Health Research (FRN-42392 and FRN-152986). EL is recipient of the CIHR phase II clinician-scientist award. CG holds a Canada Research Chair in Pharmacogenomics. AL receives graduate scholarships from the “Fonds d’enseignement et de recherche” of the Faculty of pharmacy and the “Fonds de Recherche du Québec – Santé”.

DMD #86330

Legends For Figures

Fig.1. Specificity of the novel monoclonal antibody EL-2B17mAb directed against the UGT2B17 protein. **A.** Recombinant human UGT2Bs in Supersomes (0.5 μ g); **B.** Pooled human liver microsomes (HLM), human intestine microsomes (HIM) and human kidney microsomes (HKM) (10 μ g); **C.** Pooled HLM (2B17 +) and liver microsomes from an individual carrying no *UGT2B17* gene copy (2B17 -). The position of molecular weight markers are given on the left. Arrow indicates the molecular weight of UGTs.

Fig.2. Immunohistochemical detection of UGT2B17 with EL-2B17mAb in a normal human liver. **A.** Overview of labeling distribution. Bile ducts (orange arrows) are strongly labeled whereas staining intensity of hepatocytes in the portal and central vein areas is variable. Bar represents 500 μ m. **B.** Enlarged view of a periportal area. Nuclei and cytoplasm of bile duct epithelial cells (thin black arrows) are strongly stained. Hepatocytes (large blue arrows) are variably stained, with a predominant nuclear labeling. Inflammatory cells of sinusoidal spaces are also labeled (red arrows). **C.** Enlarged view of the central vein area, showing a weaker labeling of hepatocytes (large blue arrows). In **B** and **C**, bars represent 100 μ m. The liver shown corresponds to liver A in Figure S3.

Fig.3. Correlation between UGT2B17 protein expression in human liver microsomal samples (n=29) determined by mass spectrometry (MS) and immunoblotting (WB) using EL-2B17mAb. Spearman correlation coefficient (r) and corresponding *P* value are given.

DMD #86330

Fig.4. UGT2B17 protein abundance in liver samples according to *UGT2B17* gene copy number (n=48). Quantification of UGT2B17 protein expression levels was determined by mass spectrometry. The *P* values were determined using the Kruskal Wallis one-way analysis of variance and corrected by Bonferroni. ** $P < 0.01$; *** $P < 0.001$.

Fig.5. Frequencies of UGT2B17 gene variations in diverse ethnic groups. A. *UGT2B17* gene copy number variation. Frequencies were taken from Xue et al., 2008. **B.** Allele frequencies of rs59678213 and rs6817882; **C.** Linkage disequilibrium between rs59678213 and rs6817882. For B and C, data were obtained from the 1000 Genomes phase 3 project. Individuals from European correspond to CEU Utah Residents (CEPH), Chinese to CHB Han Chinese in Beijing, China; Japanese to JPT Japanese in Tokyo, Japan; and African to YRI Yoruba in Ibadan, Nigeria.

Fig.6. UGT2B17 protein abundance in human liver is driven by *FOXA1* rs59678213A>G status. A. UGT2B17 expression levels in liver samples (n=32) according to *UGT2B17* gene copy number and the rs59678213A>G genotype. UGT2B17 protein levels were as determined by immunoblotting (WB); **B.** UGT2B17 protein levels assessed by mass spectrometry in human liver microsomes (n=48) are stratified by *UGT2B17* gene copy number and the rs59678213A>G status; **C.** UGT2B17 protein levels as in **B** are grouped according to rs59678213 in individuals with at least one gene copy. Significance was determined using the Kruskal Wallis one-way analysis of variance and were corrected by Bonferroni. ** $P < 0.01$; *** $P < 0.001$.

DMD #86330

Table 1. Protein sequence alignment of the antigen peptide of UGT2B17 with the corresponding sequence of related UGT2B family members.

| UGT proteins | Accession Number | Sequence | Identity with UGT2B17 (%) | |
|--------------|------------------|---|---------------------------|-------------|
| | | | Antigen region | Full-length |
| UGT2B17 | O75795 | ⁸³ KNDLEDFFMKMFDRW ^{TY} ₉₉ | | |
| UGT2B4 | P06133 | ⁸³ KTEFEDI IKQLVKRWAE ₉₉ | 29.4 | 78.1 |
| UGT2B7 | P16662 | ⁸³ KTELENFIM QQIKRWSD ₉₉ | 41.2 | 76.8 |
| UGT2B10 | P36537 | ⁸² KTEFENIIM QLVKRLSE ₉₈ | 23.5 | 76.8 |
| UGT2B11 | O75310 | ⁸³ KTEFENIIM QQVKRWSD ₉₉ | 29.4 | 76.6 |
| UGT2B15 | P54855 | ⁸³ KNYLED SLLKILDRWIY ₉₉ | 58.8 | 94.2 |
| UGT2B28 | Q9BY64 | ⁸³ KTEFENIIM QQVKRWSD ₉₉ | 29.4 | 75.3 |

Amino acid sequences of other human UGT2B corresponding to UGT2B17 residues 83-99, used as the antigen for the antibody production, are shown. Amino acids that are identical to UGT2B17 are indicated in bold. The sequence alignment was performed using Clustal Omega.

Figure 1




Figure 2




Figure 3






Figure 5




C

Linkage disequilibrium between rs59678213 and rs6817882

| | European | Chinese | Japanese | African |
|-------|----------|---------|----------|---------|
| r^2 | 0.93 | 0.63 | 0.45 | 0.94 |
| D' | 1.00 | 0.95 | 1.00 | 1.00 |

Figure 6



Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody

Jean-Philippe Émond, Adrien Labriet, Sylvie Desjardins, Michèle Rouleau, Lyne Villeneuve, Hélène Hovington, Hervé Brisson, Louis Lacombe, David Simonyan, Patrick Caron, Martine Périgny, Bernard Têtu, John K. Fallon, Kathrin Klein, Philip C. Smith, Ulrich M. Zanger, Chantal Guillemette[†] and Eric Lévesque[†]


Supplemental Table 1. Frequencies of the *UGT2B17* gene copy deletion and its promoter variant rs59678213A>G in individual liver samples quantified by MS (n=48). *UGT2B17* gene copy deletion is indicated by "-".

| UGT2B17 diplotypes | Frequency (%) |
|--------------------|---------------|
| -/- | 18.8 |
| G/G | 22.9 |
| A/A | 4.2 |
| -/G | 22.9 |
| -/A | 20.8 |
| G/A | 10.4 |


Supplemental Table 2. UGT2B17 protein abundance (in pmol/mg protein) assessed by MS according to UGT2B17 diplotypes in 48 individuals

The indication "-" indicates no *UGT2B17* gene copy.


| UGT2B17 diplotypes (CNV and rs59678213) | n | Mean | Median | Q1; Q3 | Frequency (%) |
|--|----------|-------------|---------------|---------------|--------------------------|
| - / - | 9 | 0.05 | 0.01 | 0.00; 0.07 | 18.8 |
| - / G G / G | 22 | 0.77 | 0.31 | 0.27; 0.36 | 45.8 |
| - / A G / A A / A | 17 | 11.30 | 12.85 | 4.03; 21.84 | 35.4 |



Supplemental Fig.1: Schematic representation of the *UGT2B17* gene and mRNA and protein quantification strategies. The following features are represented: the binding site of the FOXA1 transcription factor (Hu et al., 2010), the variant rs59678213, the 5'untranslated region (5'UTR), exon (ex) 1-3 of the *UGT2B17* gene, the position of the qPCR primers (arrows) used to measure *UGT2B17* mRNA expression, the position and sequence of the immunogenic peptide used to raise EL-2B17mAb and the signature peptide for mass spectrometry quantification (MS).



Supplemental Fig.2. Specificity of EL-2B17mAb for UGT2B17. Microsomal fractions (10 μ g) of HEK293 cells expressing each of the recombinant human UGT2B enzymes were immunoblotted with EL-2B17mAb. UGT2B17 was specifically detected (arrow) but not the other six human UGT2Bs. n.s., non specific detection of lower mobility proteins, observed in the cell line HEK293.




E


| Livers | A | | B | | C | | D | |
|---------------------------|-------|-----|-------|------|-------|-----|-----|-----|
| | N+ | C+ | N+ | C+ | N+ | C+ | N+ | C+ |
| Periportal hepatocytes | 50-75 | 80 | 75-80 | 5-10 | 50-75 | 0 | 1-5 | 0 |
| Centrilobular hepatocytes | 25-50 | 0-2 | 50 | 0 | 25-50 | 0 | 0 | 0 |
| Bile ducts | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |

¹Percent labeling represents the proportion of cells labeled in the nucleus (N) and the cytoplasm (C).


Supplemental Fig.3. Immunohistochemical detection of UGT2B17 with EL-2B17mAb in four normal human livers. A. Overview of liver *A*. **B.** Overview of liver *B*. **C.** Overview of liver *C*. **D.** Overview of liver *D*. In each liver, bile ducts (orange arrows) are strongly to moderately labeled whereas staining intensity of hepatocytes is variable. **E.** Subcellular distribution of labeling in each liver. Bars represent 500 μ m.




Supplemental Fig.4. Quantification of the UGT2B17 by immunoblot in human liver microsomes. Microsomal fraction (10 μ g) from 15 individual livers was screened with the monoclonal EL-2B17mAb (upper panels) and the pan-UGT2B polyclonal antibody EL-93 (lower panels). The *UGT2B17* genotype status for the *FOXA1* genetic variant rs59678213 and the number of *UGT2B17* gene copy are as indicated. "-" indicates a deleted copy. Commercial pools of human liver microsomes (HLM) and intestinal microsomes (HIM) are displayed as positive controls.



Supplemental Fig.5. UGT2B17 protein abundance assessed by immunoblot with EL-2B17mAb in two individuals homozygous for rs59678213A>G. Analysis of pooled human liver microsomes (HLM) and microsomes from two liver samples from individuals homozygous for the rs59678213A or G allele. The arrow indicates the UGT2B17 enzyme.



Supplemental Fig.6. UGT2B17 enzyme expression in prostate cancer cell lines. Microsomal preparations (10 μ g) were probed with the monoclonal EL-2B17mAb. The arrow indicates the UGT2B17 protein detected. Non-specific detection of lower mobility proteins (n.s.) is observed in prostate cell lines. The *UGT2B17* genotype status for the *FOXA1* genetic variant rs59678213 and the number of *UGT2B17* gene copy are as indicated. "-" indicates a deleted copy. A pooled human liver microsomal sample (HLM) served as a positive control.



Supplemental Fig.7. Influence of rs59678213A>G and rs6817882A>G variations in the *UGT2B17* promoter on luciferase reporter gene activity in liver and prostate cancer cells. A. Schematic representation of the *UGT2B17* promoter region included in the luciferase constructs. Coordinates are relative to the translation initiation codon (+1). Luciferase activity was measured 48h after transient transfection of cell models. **B.** HuH7; **C.** LNCaP; **D.** LAPC4. Experiments were performed at least twice in triplicates. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.